| TP63 mRNA expression in normal prostate tissue is retained in reduced amounts in prostate cancer, and a functional TP63 mutation was identified in one prostate tumor. If TP63 is a prostate cancer gene it likely functions as a tumor suppressor. | prostate, |
| Fancd2-Ub activates the transcription of the tumor suppressor TAp63, thereby promoting cellular senescence and blocking skin tumorigenesis. | skin, |
| Studies suggest that the presence of dual specificity phosphatase 22 (DUSP22) and p63 tumor suppressor protein (TP63) rearrangements might be useful to support a diagnosis of anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALCL). | lymphoma, |
| The data from this study showed that p63 was a tumor suppressor mainly through regulating PTEN in chondrosarcoma cells. | sarcoma, |
| Emerging evidence in this review discusses a key survival/death checkpoint in both peripheral and central neurons that involves the p53 tumor suppressor and its newly discovered family members, p73 and p63. | None |
| By a novel, reversible dynamic mechanism TNF-alpha-induced c-REL/DeltaNp63alpha interactions inactivate tumor suppressor TAp73 function, promoting TNF-alpha resistance & cell survival in cancers with mtTP53. | None |
| of mTORC1 signaling to 4E-BP1 requires the coordinated activity of two tumor suppressors, p53 and p63. In contrast, suppression of S6K1 and ribosomal protein S6 phosphorylation by DNA damage is Akt-dependent. | None |
| Our work shows that shorter TAp63 isoforms (TAp63beta/gamma) are specifically induced in human keratinocytes and cooperate with Notch signaling to activate transcription of late differentiation genes supporting their role as putative tumor suppressors. | None |
| Tumor suppressor p63 regulates expression of ubiquitin ligase PIRH2. | None |
| Data suggest that this the selective targeting of genes by tumor suppressor protein p63 (p63) correlates with subtle, but measurable transcriptional differences in mouse and human keratinocytes that converges on major metabolic processes, which often exhibit species-specific trends. | None |
| p63 may act as either an oncogene or a tumor suppressor gene in different scenarios: TA isoforms of p63 gene are generally tumor-suppressive through repressing cell proliferation, survival and metastasis; DeltaN isoforms, however, may initiate tumorigenesis via promoting cell proliferation and survival. (Review) | None |
| P63 role and expression during tumor suppression.HES1 and ECM1 are transcriptionally repressed by p63. | None |
| Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis. | HNSC, |
| p63 and p73 expression may represent an early event in head and neck squamous carcinoma tumorigenesis and may function as oncogenes in the development of these tumors. | HNSC, |
| findings indicate a contribution by p63 in cell invasion and migration, supporting an oncogenic role for p63 in squamous cell carcinoma of the head and neck | HNSC, |
| Np63 may play an oncogenic role in transitional cell carcinoma of the bladder progression through promoting cell survival and proliferation | bladder, |
| DeltaNp63alpha is an oncogene that targets chromatin remodeler Lsh to drive skin stem cell proliferation and tumorigenesis. | skin, |
| HCC1806 cells endogenously express p63, mainly as the DeltaNp63alpha isoform. Endogenous p63 is required to suppress the expression of luminal markers and maintain the basal epithelial phenotype, but p63 loss is insufficient to induce full luminal-type differentiation. p63 exerts multiple pro-oncogenic effects on cell differentiation, proliferation and adhesion in basal-like breast cancers. | liver,breast, |
| ACTL6A and p63 collaborate as oncogenic drivers in head and neck squamous cell carcinoma (HNSCC). | HNSC, |
| AIS is an oncogene amplified in squamous cell carcinoma. | None |